Assistance Publique-Hôpitaux de Paris, Hospital Paul-Brousse, Villejuif, France (D.M., J.H., E.G., R.S.,); INSERM U935, Villejuif, France (D.M., C.D., F.H.-R., C.B.); University Paris-Sud, Villejuif, France (D.M., J.H., C.D., R.M., F.H.-R., C.B., R.S.); University Paris-Saclay, Paris, France (D.M., J.H., C.D., R.M., F.H.-R., C.B., R.S.); University of Urbino Carlo Bo, Urbino, Italy (L.R., F.P., M.M.); INSERM U1193, Villejuif, France (J.H., R.S.); INSERM U1197, Villejuif, France (R.M.); INRA-AgroParisTech, UMR 782 GMPA, Thiverval-Grignon, France (P.Bo.); Institut Jean-Pierre Bourgin, INRA-AgroParisTech, University Paris-Saclay, Versailles, France (P.Br.); CRH-Department of Protein Biochemistry and Proteomics, Palacký University, Olomouc, Czech Republic (D.K.); YGM Consult SAS, Paris, France (Y.G.-M.); CNRS UMR 8601, Paris, France (J.D.); Assistance Publique-Hôpitaux de Paris, Hospital Necker-Enfants Malades, Paris. France (B.C.-V.); and University Paris-Descartes, Paris, France (B.C.-V., J.D.)
Assistance Publique-Hôpitaux de Paris, Hospital Paul-Brousse, Villejuif, France (D.M., J.H., E.G., R.S.,); INSERM U935, Villejuif, France (D.M., C.D., F.H.-R., C.B.); University Paris-Sud, Villejuif, France (D.M., J.H., C.D., R.M., F.H.-R., C.B., R.S.); University Paris-Saclay, Paris, France (D.M., J.H., C.D., R.M., F.H.-R., C.B., R.S.); University of Urbino Carlo Bo, Urbino, Italy (L.R., F.P., M.M.); INSERM U1193, Villejuif, France (J.H., R.S.); INSERM U1197, Villejuif, France (R.M.); INRA-AgroParisTech, UMR 782 GMPA, Thiverval-Grignon, France (P.Bo.); Institut Jean-Pierre Bourgin, INRA-AgroParisTech, University Paris-Saclay, Versailles, France (P.Br.); CRH-Department of Protein Biochemistry and Proteomics, Palacký University, Olomouc, Czech Republic (D.K.); YGM Consult SAS, Paris, France (Y.G.-M.); CNRS UMR 8601, Paris, France (J.D.); Assistance Publique-Hôpitaux de Paris, Hospital Necker-Enfants Malades, Paris. France (B.C.-V.); and University Paris-Descartes, Paris, France (B.C.-V., J.D.).
J Pharmacol Exp Ther. 2019 Jun;369(3):489-502. doi: 10.1124/jpet.119.256537. Epub 2019 Apr 2.
Methionine deprivation induces growth arrest and death of cancer cells. To eliminate l-methionine we produced, purified, and characterized the recombinant pyridoxal 5'-phosphate (PLP)-dependent l-methionine -lyase (MGL)- BL929 from the cheese-ripening Transformation of an strain with the gene from optimized for expression led to production of the MGL-BL929. Elimination of l-methionine and cytotoxicity in vitro were assessed, and methylation-sensitive epigenetics was explored for changes resulting from exposure of cancer cells to the enzyme. A bioreactor was built by encapsulation of the protein in human erythrocytes to achieve sustained elimination of l-methionine in extracellular fluids. Catalysis was limited to ,-elimination of l-methionine and l-homocysteine. The enzyme had no activity on other sulfur-containing amino acids. Enzyme activity decreased in presence of serum albumin or plasma resulting from reduction of PLP availability. Elimination of l-methionine induced cytotoxicity on a vast panel of human cancer cell lines and spared normal cells. Exposure of colorectal carcinoma cells to the MGL-BL929 reduced methyl-CpG levels of hypermethylated gene promoters including that of CDKN2A, whose mRNA expression was increased, together with a decrease in global histone H3 dimethyl lysine 9. The MGL-erythrocyte bioreactor durably preserves enzyme activity in vitro and strongly eliminates l-methionine from medium.
蛋氨酸剥夺可诱导癌细胞生长停滞和死亡。为了消除 l-蛋氨酸,我们生产、纯化并鉴定了来自奶酪成熟的重组吡哆醛 5′-磷酸(PLP)依赖性 l-蛋氨酸 - 裂解酶(MGL)-BL929,该酶来自经优化用于表达的基因 。通过转化基因 ,可以产生 MGL-BL929。在体外评估了 l-蛋氨酸的消除和细胞毒性,并探索了癌症细胞暴露于酶后导致的甲基化敏感表观遗传学变化。通过将蛋白质封装在人红细胞中构建生物反应器,以实现细胞外液中 l-蛋氨酸的持续消除。催化作用仅限于 l-蛋氨酸和 l-高半胱氨酸的 - 消除。该酶对其他含硫氨基酸没有活性。由于 PLP 可用性降低,白蛋白或血浆的存在会降低酶活性。该酶在广泛的人类癌细胞系上消除 l-蛋氨酸诱导细胞毒性,而对正常细胞没有影响。暴露于 MGL-BL929 的结肠直肠癌细胞降低了包括 CDKN2A 在内的超甲基化基因启动子的甲基化-CpG 水平,其 mRNA 表达增加,同时组蛋白 H3 二甲基赖氨酸 9 的全局水平降低。MGL-红细胞生物反应器在体外持久地保存酶活性,并从培养基中强烈消除 l-蛋氨酸。